Understanding and Predicting Breast Cancer Events After Treatment

Inclusion Criteria for Women with Stage I - III Breast Cancer:

Stage I-III female breast cancer (including inflammatory and newly diagnosed or locally recurrent breast cancer) but not metastatic breast cancer being treated with curative intent
> 18 years old
Scheduled to receive chemotherapy and/or estrogen antagonist aromatase inhibitors (anastrozole [Arimidex], letrozole [Femara], exemestane [Aromasin]).
Able to hold breath for 10 seconds
ECOG performance status 0 -2
Able to walk at least 2 blocks without chest pain, dyspnea, shortness of breath or fainting
Able to exercise on a treadmill or stationary cycle
Participants in other ongoing clinical trials are eligible for this study

Exclusion Criteria for Women with Stage I-III Breast Cancer:

Those with ferromagnetic cerebral aneurysm clips or other intracranial metal; pacemakers, defibrillators, functioning neurostimulator devices or other implanted non-compatible MRI devices (patients with tissue expanders will not be excluded)
If previously measured, known LVEF <50%
Symptomatic claustrophobia
Unable to provide informed consent
At the beginning of the study, pregnant women and women who are breast-feeding will not be enrolled.
Severe pulmonary hypertension

Within the past 6 months:

Acute pulmonary embolus
Deep vein thrombosis

Within the past month:

Heart attack
Unstable or stable angina (cardiac chest pain)
Left main coronary artery disease
Symptomatic heart failure
Uncontrolled hypertension (SBP > 180 mm Hg or DBP > 120 mm Hg)
Severe valvular heart disease
Uncontrolled metabolic disease (diabetes with fasting BS >300 mg/dl, thyrotoxicosis, myxedema)
Aortic aneurism (>45 mm diameter) or aortic dissection
Uncontrolled slow or fast heart rhythm causing symptoms or hemodynamic compromise
Hypertrophic obstructive cardiomyopathy
Patient does not understand English

Inclusion Criteria for Women Free of Cancer for Comparison:

Healthy female without known coronary artery disease > 18 years old
Able to hold breath 10 seconds
ECOG performance status = 0 or 1
Able to walk at least 2 blocks without chest pain, dyspnea, shortness of breath or fainting
Able to exercise on a treadmill or stationary cycle
No personal history of cancer other than superficial skin cancers
Has never received chemotherapy, radiation therapy, immunotherapy, or had breast cancer related surgery
If previously measured, LVEF ≥ 50%

Exclusion Criteria for Women Free of Cancer for Comparison:

Inflammatory conditions such as lupus or inflammatory bowel disease
Overt coronary artery disease or heart failure
Those with ferromagnetic cerebral aneurysm clips or other intracranial metal; pacemakers, defibrillators, functioning neurostimulator devices or other implanted non-compatible MRI devices
Symptomatic claustrophobia
Unable to provide informed consent
At the beginning of the study, pregnant women or women who are breast feeding will not be enrolled.
Severe pulmonary hypertension

Within the past 6 months:

Acute pulmonary embolus
Deep vein thrombosis

Within the past month:

Heart attack
Unstable or stable angina (cardiac chest pain)
Left main coronary artery disease
Symptomatic heart failure
Uncontrolled hypertension (SBP > 180 mm Hg or DBP > 120 mm Hg)
Severe valvular heart disease
Uncontrolled metabolic disease (diabetes with fasting BS >300 mg/dl, thyrotoxicosis, myxedema)
Aortic aneurism (>45 mm diameter) or aortic dissection
Uncontrolled slow or fast heart rhythm causing symptoms or hemodynamic compromise
Hypertrophic obstructive cardiomyopathy
Patient does not understand English